Helius.jpg
Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device -- Agreement extends existing partnership ---- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area and will greatly strengthen Helius’s presence in the...
Helius.jpg
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
09. März 2023 16:05 ET | Helius Medical Technologies, Inc.
-- Full year 2022 revenue of $0.8 million, an increase of 51% over 2021 -- -- Year-end cash balance of $14.5 million -- -- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 09, 2023 ...
Helius.jpg
Helius Medical Technologies Announces Authorization from Health Canada to Market Portable Neuromodulation Stimulator (PoNS®) Device for the Treatment of Gait Deficit Due to Mild and Moderate Symptoms from Stroke
09. März 2023 07:05 ET | Helius Medical Technologies, Inc.
NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach...
Helius.jpg
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
06. März 2023 07:30 ET | Helius Medical Technologies, Inc.
NEWTOWN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius.jpg
Helius Medical Technologies to Present at the 35th Annual ROTH Conference
02. März 2023 16:05 ET | Helius Medical Technologies, Inc.
NEWTOWN, Pa., March 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius.jpg
Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting
15. Februar 2023 07:05 ET | Helius Medical Technologies, Inc.
NEWTOWN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and...
Helius.jpg
Helius Medical Technologies, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022
23. Januar 2023 07:05 ET | Helius Medical Technologies, Inc.
-- Q4 2022 revenue projected to range from $275,000 to $285,000 ---- Full year 2022 revenue projected to range from $780,000 to $790,000 ---- Unaudited year end cash balance of $14.5 million -- ...
Helius.jpg
Helius Medical Technologies to Present at the Virtual Q1 Investor Summit Microcap Event, January 26, 2023
19. Januar 2023 09:00 ET | Helius Medical Technologies, Inc.
NEWTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced...
Helius.jpg
Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program
10. Januar 2023 07:05 ET | Helius Medical Technologies, Inc.
-- Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS® therapy for gait...
Helius.jpg
Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis
05. Januar 2023 07:41 ET | Helius Medical Technologies, Inc.
NEWTOWN, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) today announced the extension of a program that puts the company’s Portable Neuromodulation Stimulator...